Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 100, Issue , 2014, Pages 230-235

  Korostelev, Marie ^a   Bihan, Kevin ^a   Ferreol, Lison ^a   Tissot, Nadine ^a   Hulot, Jean Sebastien ^a,b,c   Funck Brentano, Christian ^a,b,c   Zahr, Noël ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institute OfCardiometabolism and Nutrition   (France)

Author keywords

Dabigatran; LC MS MS; Mass spectrometry; Rivaroxaban; TSOAC

Indexed keywords

DABIGATRAN; DABIGATRAN ETEXILATE; RIVAROXABAN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; CARBON 13;

ARTICLE; COLLISIONALLY ACTIVATED DISSOCIATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PRECIPITATION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SIGNAL NOISE RATIO; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; BLOOD; CALIBRATION; CHEMICAL STRUCTURE; COLD; DRUG MONITORING; LIMIT OF DETECTION; PROCEDURES; REPRODUCIBILITY; STANDARD; STANDARDS; STATISTICAL MODEL; TIME; VALIDATION STUDY; ACCURACY; PLASMA; PROCESS OPTIMIZATION;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLD TEMPERATURE; DRUG MONITORING; DRUG STABILITY; FACTOR XA INHIBITORS; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; MOLECULAR STRUCTURE; MORPHOLINES; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; THIOPHENES; TIME FACTORS;

EID: 84906734062     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.08.011     Document Type: Article

References (11)

1. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365(September (10)):883-891. PMID: 21830957.
2. Wolowacz S.E., Roskell N.S., Plumb J.M., Caprini J.A., Eriksson B.I. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb. Haemost. 2009, 101(January (1)):77-85. PMID: 19132192.
3. Bounameaux H., Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J. Thromb. Haemost. 2010, 8(April (4)):627-630. PMID: 20088926.
4. Stangier J., Rathgen K., Stahle H., Gansser D., Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol. 2007, 64(September (3)):292-303. PMID: 17506785. PMCID: 2000643.
5. Delavenne X., Moracchini J., Laporte S., Mismetti P., Basset T. UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma. J. Pharm. Biomed. Anal. 2012, 58(January):152-156. PMID: 21996066.
6. Douxfils J., Dogne J.M., Mullier F., Chatelain B., Ronquist-Nii Y., Malmstrom R.E., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb. Haemost. 2013, 110(September (3)):543-549. PMID: 23783171.
7. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogne J.M., et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb. Haemost. 2013, 110(October (4)):723-731. PMID: 23846172.
8. Hawes E.M., Deal A.M., Funk-Adcock D., Gosselin R., Jeanneret C., Cook A.M., et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J. Thromb. Haemost. 2013, 11(August (8)):1493-1502. PMID: 23718677.
9. Francart S.J., Hawes E.M., Deal A.M., Adcock D.M., Gosselin R., Jeanneret C., et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb. Haemost. 2014, 111(January (5)). PMID: 24401946.
10. Gous T., Couchman L., Patel J.P., Paradzai C., Arya R., Flanagan R.J. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther. Drug Monit. 2014, April. PMID: 24695356.
11. Schmitz E.M.H., van den Heuvel D., Boonen K., van Dongen J.L.J., Brunsveld L., van de Kerkhof D. Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring. Ned. Tijdschr. Klin. Chem. Labgeneesk. 2013, 38:142-144.